194 related articles for article (PubMed ID: 36204571)
1. Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis.
Shi Y; Liu J; Liu C; Shuang X; Yang C; Qiao W; Dong G
Front Cardiovasc Med; 2022; 9():937291. PubMed ID: 36204571
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction.
Song Y; Li F; Xu Y; Liu Y; Wang Y; Han X; Fan Y; Cao J; Luo J; Sun A; Hu K; Zhou J; Ge J
Int J Cardiol; 2020 Apr; 304():95-100. PubMed ID: 32019693
[TBL] [Abstract][Full Text] [Related]
3. ST2 in heart failure with preserved and reduced ejection fraction.
Najjar E; Faxén UL; Hage C; Donal E; Daubert JC; Linde C; Lund LH
Scand Cardiovasc J; 2019 Feb; 53(1):21-27. PubMed ID: 30776920
[TBL] [Abstract][Full Text] [Related]
4. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.
Rabkin SW; Tang JKK
Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction.
Friões F; Lourenço P; Laszczynska O; Almeida PB; Guimarães JT; Januzzi JL; Azevedo A; Bettencourt P
Clin Res Cardiol; 2015 Jun; 104(6):491-9. PubMed ID: 25586507
[TBL] [Abstract][Full Text] [Related]
8. Association of point-of-care testing for sST2 with clinical outcomes in patients hospitalized with heart failure.
Chen Y; Guan J; Qi C; Wu Y; Wang J; Zhao X; Li X; He C; Zhang J; Zhang Y
ESC Heart Fail; 2024 May; ():. PubMed ID: 38773746
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with anemia and renal dysfunction in hospitalized heart failure with preserved ejection fraction (from the CN-HF registry).
Jin X; Cao J; Zhou J; Wang Y; Han X; Song Y; Fan Y; Chen Z; Xu D; Yang X; Dong W; Li L; Chen L; Zhong Q; Fu M; Hu K; Zhou J; Ge J;
Int J Cardiol Heart Vasc; 2019 Dec; 25():100415. PubMed ID: 31508483
[TBL] [Abstract][Full Text] [Related]
10. Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction.
Cui Y; Qi X; Huang A; Li J; Hou W; Liu K
Med Sci Monit; 2018 Jul; 24():5139-5146. PubMed ID: 30039808
[TBL] [Abstract][Full Text] [Related]
11. Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study.
Li F; Xu M; Fu M; Cui X; Lian Z; Xin H; Zhou J; Ge J
BMC Cardiovasc Disord; 2021 Aug; 21(1):396. PubMed ID: 34404341
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction - A multicenter study.
Bahuleyan CG; Alummoottil GK; Abdullakutty J; Lordson AJ; Babu S; Krishnakumar VV; Pillai AM; Abraham G; Dilip MN
Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S79-S84. PubMed ID: 30122243
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis.
Shi Y; Dong G; Liu J; Shuang X; Liu C; Yang C; Qing W; Qiao W
Front Cardiovasc Med; 2022; 9():854501. PubMed ID: 35498052
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.
Aimo A; Vergaro G; Ripoli A; Bayes-Genis A; Pascual Figal DA; de Boer RA; Lassus J; Mebazaa A; Gayat E; Breidthardt T; Sabti Z; Mueller C; Brunner-La Rocca HP; Tang WH; Grodin JL; Zhang Y; Bettencourt P; Maisel AS; Passino C; Januzzi JL; Emdin M
JACC Heart Fail; 2017 Apr; 5(4):287-296. PubMed ID: 28189578
[TBL] [Abstract][Full Text] [Related]
16. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.
Pan W; Yang D; Yu P; Yu H
BMC Cardiovasc Disord; 2020 Apr; 20(1):208. PubMed ID: 32354356
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
18. Elevated soluble ST2 and depression increased the risk of all-cause mortality and hospitalization in patients with heart failure.
Xu SD; Su GH; Lu YX; Shuai XX; Tao XF; Meng YD; Luo P
Int Heart J; 2014; 55(5):445-50. PubMed ID: 25070116
[TBL] [Abstract][Full Text] [Related]
19. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction.
Zach V; Bähr FL; Edelmann F
Card Fail Rev; 2020 Mar; 6():1-7. PubMed ID: 32257387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
